Cortexyme, a company focusing on treatments for degenerative diseases, entered into a deal to acquire Novosteo, which plays in the rare disease space. Once the deal is finalized, the merged companies will operate under the name Quince Therapeutics and trade under the ticker symbol QNCX.

Biopharma companies Gennao Bio and Juno Diagnostics raised a combined $65 million in Series A funding rounds.